They’re constantly trying to pinch the compounding pharmacies. As noted above, important distinction between 503a and 503b. The reputable 503b pharmacies (and most of their respective products) aren’t going anywhere, though they are under constant pressure from multiple angles (essential copy disputes, “do not compound” list modifications, big pharma intimidation tactics, etc). On a related note, the FDA recently placed GHRPs on the category 3 “do not compound” list. My team is sending out a notification this week regarding same. By the end of the year any compounding pharmacy still producing GHRP 2 and GHRP 6 will be in violation. Notably, this does NOT apply to ipamorelin or GHRH (sermorelin).